bi_microparts_image

Boehringer’s France restructure will cull over 300 jobs

pharmafile | December 11, 2018 | News story | Manufacturing and Production Boehringer, Sanofi, job cuts, pharma 

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.

The German drug company confirmed the plans to unions, explaining that the move is designed to reorganise operations in and around its hub in the French city of Lyon.

The restructure comes in the wake of an asset swap between Boehringer and Sanofi, with the former trading its consumer health division for the latter’s animal health arm Merial last year – a transaction worth $20 billion.

In total, Sanofi intends to axe 327 positions from a total of 2,800, which will also make room for the introduction of 32 new roles. The plan was confirmed by Jean Scheftsik de Szolnok, Boehringer’s Chairman for France, who also noted that those affected would be offered voluntary severance packages, though he could not say exactly when this would be the case.

Advertisement

Matt Fellows

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

The Gateway to Local Adoption Series

Latest content